Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Portfolio Pulse from Vandana Singh
The U.S. Department of Health and Human Services has released final guidance for the second cycle of the Medicare Drug Price Negotiation Program, expected to save $1.5 billion in out-of-pocket costs for Medicare recipients. The program will negotiate prices for up to 15 additional drugs, including those from Novo Nordisk, Pfizer, GSK, Teva, and Abbvie, with new prices effective in 2027.
October 03, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Abbvie's irritable bowel syndrome treatment Linzess is included in the second cycle of Medicare's Drug Price Negotiation Program, potentially leading to lower prices by 2027.
Inclusion in the Medicare Drug Price Negotiation Program suggests potential price reductions for Linzess, which could impact Abbvie's revenue from this drug.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
GSK's asthma treatment Trelegy Ellipta is included in the second cycle of Medicare's Drug Price Negotiation Program, potentially leading to lower prices by 2027.
Inclusion in the Medicare Drug Price Negotiation Program suggests potential price reductions for Trelegy Ellipta, which could impact GSK's revenue from this drug.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Novo Nordisk's diabetes drug Ozempic is included in the second cycle of Medicare's Drug Price Negotiation Program, potentially leading to lower prices by 2027.
Inclusion in the Medicare Drug Price Negotiation Program suggests potential price reductions for Ozempic, which could impact Novo Nordisk's revenue from this drug.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Pfizer's cancer drugs Ibrance and Xtandi are part of the second cycle of Medicare's Drug Price Negotiation Program, which may lead to reduced prices by 2027.
The inclusion of Ibrance and Xtandi in the negotiation program could lead to price reductions, potentially affecting Pfizer's revenue from these drugs.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Teva's Huntington’s disease drug Austedo is part of the second cycle of Medicare's Drug Price Negotiation Program, which may lead to reduced prices by 2027.
The inclusion of Austedo in the negotiation program could lead to price reductions, potentially affecting Teva's revenue from this drug.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80